Digital pathology image analysis algorithms

Intelligent and insightful digital pathology image analysis algorithms that empower pathologists to confidently, accurately, and objectively assess whole tissue slide images.

Find your product Contact us
Pathologist showing a colleague a digital image of an immunohistochemical stain of a tumor tissue on a computer screen

Confidence starts with clarity

Harness the power of artificial intelligence (AI) to remove time-consuming tasks from your pathology workflow and allow your team to focus on more meaningful tasks.

Pioneers in digital pathology, Roche was the first company to offer a comprehensive portfolio of FDA-cleared image analysis algorithms and digital read applications for the five key immunohistochemistry (IHC) breast markers.1,2 We have since evolved our technology, launching whole slide image analysis algorithms utilizing advanced AI tools.**

Image analysis algorithms for pathology decision support, provide analysis of VENTANA® slide scanner images stained with a Roche Tissue Diagnostics assay. The algorithms extract meaningful information from pathology slide images, so pathologists can quickly, accurately, and confidently assess whole tissue slide images.

Our integrated and ready-to-use digital pathology algorithms include:

Featured products

Software for objective, reproducible, automated scoring of VENTANA DP 200 slide images (breast) stained with the VENTANA HER2 Dual ISH DNA Probe Cocktail assay.
The VENTANA HER2 (4B5) breast cancer algorithm by navify® Digital Pathology for breast oncology is ready-to-use, fast, consistent and automated for clinical decision support.
Objective, reproducible scoring of VENTANA DP 200 slide images stained with the PD-L1 (SP263) Assay integrated into the clinical uPath software for NSCLC.
Find your product

Benefits of image analysis algorithms from Roche

For confident decision making

Our image analysis algorithms generate actionable, objective, and reproducible results. The algorithms are trained using a robust and representative data set to automatically classify cells and provide assay-specific scoring.

According to a study, an image analysis algorithm enhances pathologist reporting efficiency, demonstrating a 66.8% reduction in turnaround time.3 Pathologists can make confident decisions based on quick, accurate analysis.

Integrated and ready-to-use digital pathology algorithms

Fully embedded into navify Digital Pathology enterprise software, Roche image analysis algorithms enable seamless viewing, aligning, syncing, sharing, and reporting. The AI-powered algorithms, streamline processes, removing time-consuming tasks for a more efficient and productive pathology workflow.

Ensuring reproducible results

Roche algorithms are validated on a robust, reliable, and representative set of benchmark data as part of the end-to-end Roche pathology laboratory ecosystem. Responsible AI principles are included in the development process to ensure standardization, transparency, and reproducibility of our AI in your lab.

Expert pathologists are included in every step of the development process.

Roche uPath Image Analysis Algorithms* are part of a complete solution:

Contact us

Do you have questions about our products or services? We’re here to help. Fill out the form to contact a Roche representative.

Related health topics

*For research use only. Not for use in diagnostic procedures. Roche is dedicated to clinically deploying its Digital Pathology Solutions and is actively pursuing approval/clearance for our portfolio of products. 

**Our current portfolio available on the market is RUO only. Not for use in diagnostic procedures.

Roche Digital Pathology Dx, including navify Digital Pathology, is intended for specific clinical applications and is for research and educational use for other applications. Please review the product labeling for compliance before utilization. 

NAVIFY and VENTANA are trademarks of Roche. Other product names and trademarks are the property of their respective owners.


References:

  1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K111543 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K121516 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K130515 ;  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K111755 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K121033 ;  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K111872 ;  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K142965 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K122143 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K111869 ; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K140465 ;
  2. https://www.prnewswire.com/news-releases/ventana-receives-fda-clearance-for-estrogen-receptor-er-image-analysis-and-digital-read-application-for-breast-cancer-234579611.html. Accessed on April 29, 2025.
  3. Gough, M. et al. Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer. Histopathology. 2023 Jun 23; 83:647-656. https://onlinelibrary.wiley.com/doi/10.1111/his.15000. Accessed on April 29, 2025.